glp-1 receptor agonists should be avoided in patients with and next-generation metabolic hormone therapies chronic kidney disease GLP-1 Receptor Agonists Explained for

Tariffs on imported active pharmaceutical ingredients (APIs) or components used in the manufacturing of GLP-1 receptor agonists could potentially increase production costs for US-based manufacturers

In primary human hepatocytes, GLP-1 RAs reduced lipogenesis by approximately 24.6% compared to untreated controls

doi: 10.1016/S2213-8587(19)30249-9

Results GLP-1RA reduced major cardiovascular events (MACE) by 14% (HR = 0.86, 95% CI 0.790.94, P = 0.006) with a non-significant heterogeneity between subgroups of patients with and without cardiovascular disease (P = 0.127)

Add to cart now and take the next step in next-generation metabolic science.

This business is mainly focused on North America, where GLP-1 adoption is highest